[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2011013176A - Motivos de modificación química para inhibidores y miméticos del miarn. - Google Patents

Motivos de modificación química para inhibidores y miméticos del miarn.

Info

Publication number
MX2011013176A
MX2011013176A MX2011013176A MX2011013176A MX2011013176A MX 2011013176 A MX2011013176 A MX 2011013176A MX 2011013176 A MX2011013176 A MX 2011013176A MX 2011013176 A MX2011013176 A MX 2011013176A MX 2011013176 A MX2011013176 A MX 2011013176A
Authority
MX
Mexico
Prior art keywords
mimetics
chemical modification
mirna
mirna inhibitors
modification motifs
Prior art date
Application number
MX2011013176A
Other languages
English (en)
Inventor
Christina Yamada
William S Marshall
Original Assignee
Miragen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics filed Critical Miragen Therapeutics
Publication of MX2011013176A publication Critical patent/MX2011013176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polinucleótidos que tienen patrones químicos que dan como resultado una estabilidad, una potencia y/o una toxicidad mejoradas, en el contexto del uso como inhibidores del miARN o miméticos del miARN. Compocisiones y formulaciones farmacéuticas que comprenden dichos polinucleótidos. Métodos para tratar pacientes que padecen una infección asociada a la expresión del miARN o del ARNm.
MX2011013176A 2009-06-08 2010-06-08 Motivos de modificación química para inhibidores y miméticos del miarn. MX2011013176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18503309P 2009-06-08 2009-06-08
PCT/US2010/037821 WO2010144485A1 (en) 2009-06-08 2010-06-08 CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS

Publications (1)

Publication Number Publication Date
MX2011013176A true MX2011013176A (es) 2012-04-30

Family

ID=43309198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013176A MX2011013176A (es) 2009-06-08 2010-06-08 Motivos de modificación química para inhibidores y miméticos del miarn.

Country Status (17)

Country Link
US (2) US20120148664A1 (es)
EP (1) EP2440566A4 (es)
JP (1) JP2012529295A (es)
KR (1) KR20120047892A (es)
CN (1) CN102803284B (es)
AU (1) AU2010258875A1 (es)
BR (1) BRPI1010885A2 (es)
CA (1) CA2765129A1 (es)
EA (1) EA022757B1 (es)
GE (1) GEP20156329B (es)
MA (1) MA33488B1 (es)
MX (1) MX2011013176A (es)
NZ (1) NZ597078A (es)
SG (1) SG176716A1 (es)
UA (1) UA105390C2 (es)
WO (1) WO2010144485A1 (es)
ZA (1) ZA201109319B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
AU2011219029B2 (en) 2010-02-26 2017-02-02 Columbia University Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
JP2014504857A (ja) 2010-12-15 2014-02-27 ミラゲン セラピューティクス ロックドヌクレオチドを含むｍｉｃｒｏＲＮＡ阻害剤
CN102643807B (zh) * 2011-02-18 2015-06-03 中国科学院上海药物研究所 人miR-484的反义寡聚核苷酸及其应用
CN103747805B (zh) * 2011-04-22 2017-08-29 比奥马林技术公司 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型（dm1）的化合物
LT2702155T (lt) * 2011-04-25 2017-05-10 Regulus Therapeutics Inc. Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui
WO2012149646A1 (en) * 2011-05-05 2012-11-08 Sunnybrook Research Institute Mirna inhibitors and their uses
US9267134B2 (en) * 2011-05-09 2016-02-23 The University Court Of The University Of Glasgow Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension
JP6177243B2 (ja) 2011-10-06 2017-08-09 ミラゲン セラピューティクス， インコーポレイテッド マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御
JP2015509922A (ja) 2012-01-27 2015-04-02 プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
PT2841578T (pt) 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
PE20142404A1 (es) * 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
CN102703456B (zh) * 2012-05-15 2014-04-02 武汉生命之美科技有限公司 DAPK3基因hsa-miR-20a的作用靶位点
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
AU2013278011B2 (en) 2012-06-21 2018-09-20 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
KR102214740B1 (ko) 2013-05-01 2021-02-10 레굴루스 테라퓨틱스 인크 Mir-122를 조정하기 위한 마이크로rna 화합물 및 방법
CN103290011B (zh) * 2013-05-16 2015-09-16 南京市妇幼保健院 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-29c及其应用
CN103667441B (zh) * 2013-09-10 2016-10-19 山西医科大学第一医院 一种Hsa-miR-145-5p试剂盒及其成熟体模拟物的应用
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
CN104083761A (zh) * 2014-06-25 2014-10-08 北京大学第三医院 microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos
HK1247617A1 (zh) 2015-01-20 2018-09-28 MiRagen Therapeutics, Inc. Mir-92抑制劑及其使用
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
US11655469B2 (en) 2016-03-07 2023-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MicroRNAs and methods of their use
EP3449001B1 (en) * 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
US10874688B2 (en) * 2016-10-31 2020-12-29 Gifu University Double-stranded nucleic acid molecule and use thereof
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
CA3093572A1 (en) 2018-03-14 2019-09-19 Beth Israel Deaconess Medical Center Inhibitors of micro-rna 22
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
US11015197B2 (en) 2018-08-29 2021-05-25 Korea Institute Of Science And Technology Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite
EP4127175A4 (en) 2020-04-02 2025-01-22 Mirecule Inc TARGETED INHIBITION USING MODIFIED OLIGONUCLEOTIDES
WO2022018269A1 (en) * 2020-07-23 2022-01-27 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
EP2530157B1 (en) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CN101426912A (zh) * 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
WO2008109373A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US8288356B2 (en) * 2007-10-04 2012-10-16 Santaris Pharma A/S MicroRNAs
WO2009062169A2 (en) * 2007-11-09 2009-05-14 The Board Of Regents Of The University Of Texas System Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair

Also Published As

Publication number Publication date
CN102803284A (zh) 2012-11-28
WO2010144485A1 (en) 2010-12-16
EP2440566A1 (en) 2012-04-18
AU2010258875A1 (en) 2012-01-19
CA2765129A1 (en) 2010-12-16
CN102803284B (zh) 2015-11-25
EP2440566A4 (en) 2013-10-16
ZA201109319B (en) 2013-02-27
UA105390C2 (ru) 2014-05-12
GEP20156329B (en) 2015-07-27
US20140066491A1 (en) 2014-03-06
US20120148664A1 (en) 2012-06-14
NZ597078A (en) 2013-11-29
EA022757B1 (ru) 2016-02-29
KR20120047892A (ko) 2012-05-14
SG176716A1 (en) 2012-01-30
MA33488B1 (fr) 2012-08-01
EA201171493A1 (ru) 2012-06-29
BRPI1010885A2 (pt) 2015-09-22
JP2012529295A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
MX336381B (es) Boronatos como inhibidores de arginasa.
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
IN2012DN01233A (es)
IN2012DN02805A (es)
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY148948A (en) Catecholamine derivatives and prodrugs thereof
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX2010011217A (es) Inhibidores de piridilo para señalizacion hedgehog.
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
NZ577916A (en) Cyclopamine analogs
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IN2012DN02471A (es)
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012004780A (es) Inhibidores de akt.
IN2012DN02149A (es)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof

Legal Events

Date Code Title Description
FG Grant or registration